Navigation Links
Oncothyreon announces webcast of second quarter 2009 financial results conference call
Date:8/6/2009

SEATTLE, Aug. 6 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY), a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer, today announced that it intends to release its second quarter and year end 2009 financial results on Wednesday, August 12, 2009 after the close of the U.S. and Canadian markets. Following the release, Oncothyreon's management expects to discuss these financial results and give a general business update in a conference call at 4:30 p.m. EST.

The discussion is planned for a live webcast and can be accessed at www.oncothyreon.com under the "News Events" section. It is expected that the archive of the webcast will be available approximately one hour after completion of the discussion and will be posted on the Oncothyreon website for 30 days.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit www.oncothyreon.com.


'/>"/>
SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Oncothyreon appoints Diana Hausman as Vice President of Clinical Development
2. Oncothyreon announces presentation of long-term Stimuvax data at World Conference on Lung Cancer
3. Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer
4. Oncothyreon appoints Scott Peterson as Vice President of Research and Development
5. Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting
6. Oncothyreon announces closing of $11.1 million registered direct financing
7. Oncothyreon announces commitments to purchase $11.1 million of company securities in a registered direct financing
8. Oncothyreons PX-866 is effective in preclinical model of pulmonary fibrosis
9. Oncothyreon announces presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
10. Oncothyreon reports first quarter 2009 financial results
11. Oncothyreon regains compliance with NASDAQ listing requirements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ON , June 27, 2016 /PRNewswire/ - BIOREM Inc. ... has been advised by its major shareholders, Clean Technology ... United States based venture capital ... shares of Biorem (on a fully diluted, as converted ... the disposition of their entire equity holdings in Biorem ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created 4Sight Medical ... to the healthcare market. The company's primary focus is on new product introductions, ... strategies that are necessary to help companies efficiently bring their products to market. ...
(Date:6/24/2016)... 2016  Regular discussions on a range of subjects including ... two entities said Poloz. Speaking at a lecture ... , he pointed to the country,s inflation target, which is ... "In certain areas there ... common economic goals, why not sit down and address strategy ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a ... eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research ... by providing practical tips, tools, and strategies for clinical researchers. , “The landscape ...
Breaking Biology Technology:
(Date:4/26/2016)... DUBLIN , April 27, 2016 ... of the  "Global Multi-modal Biometrics Market 2016-2020"  report ... ) , The analysts forecast ... a CAGR of 15.49% during the period 2016-2020.  ... a number of sectors such as the healthcare, ...
(Date:4/14/2016)... TEL AVIV, Israel , April 14, 2016 /PRNewswire/ ... in Behavioral Authentication and Malware Detection, today announced the ... has already assumed the new role. Goldwerger,s ... for BioCatch, on the heels of the deployment of ... In addition, BioCatch,s behavioral biometric technology, which discerns unique ...
(Date:3/29/2016)... , March 29, 2016 ... "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to ... ink used in a variety of writing instruments, ensuring ... of originally created collectibles from athletes on LegacyXChange will ... analysis of the DNA. Bill Bollander ...
Breaking Biology News(10 mins):